Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type

HIV Medicine

Volumn 5, Issue 4, 2004, Pages 264-272

  Bogner, Johannes R ^a   Lutz, B ^b,c   Klein, H G ^c   Pollerer, C ^a   Troendle, U ^a   Goebel, F D ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OLDENBURG   (Germany)

^c IMGM LABORATORIES GMBH   (Germany)

Author keywords

AIDS; Chemokine receptor; Chemokine receptor 2; Chemokine receptor 5; Genetic polymorphism; Highly active antiretroviral therapy; HIV; Stromal derived factor 1

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR5; GENOMIC DNA; STROMAL CELL DERIVED FACTOR 1; VIRUS RNA;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA EXTRACTION; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CHEMOKINES, CXC; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; TREATMENT FAILURE;

EID: 4043112019     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00219.x     Document Type: Article

References (30)

1. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2000; 283: 381-390.
2. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-868.
3. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: a RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-1958.
4. Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 2000; 12: 1311-1318.
5. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997; 94: 1925-1930.
6. Easterbrook PJ, Rostron T, Ives N, Troop M, Gazzard BG, Rowland-Jones SL. Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J Infect Dis 1999; 180: 1096-1105.
7. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.
8. Eugen-Olsen J, Iversen AK, Benfield TL, Koppelhus U, Garred P. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 110-116.
9. Hendel H, Henon N, Lebuanec H et al. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 381-386.
10. Ioannidis JP, Rosenberg PS, Goedert JJ et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135: 782-795.
11. Kostrikis LG, Neumann AU, Thomson B et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999; 73: 10264-10271.
12. Smith MW, Dean M, Carrington M et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277: 959-965.
13. Michael NL, Louie LG, Rohrbaugh AL et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3: 1160-1162.
14. Walli R, Reinhart B, Luckow B et al. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 229-233.
15. Rizzardi GP, Morawetz RA, Vicenzi E et al. CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med 1998; 4: 252-253.
16. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, Rowland-Jones SL. CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet 1998; 351: 1632-1633.
17. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352: 866-870.
18. Mummidi S, Ahuja SS, Gonzalez E et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998; 4: 786-793.
19. Guerin S, Meyer L, Theodorou I et al. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000; 14: 2788-2790.
20. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001; 134: 978-996.
21. O'Brien TR, McDermott DH, Ioannidis JP et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14: 821-826.
22. Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuitemaker H. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J Infect Dis 2002; 186: 1726-1732.
23. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
24. Kostrikis LG, Huang Y, Moore JP et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4: 350-353.
25. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. J Am Med Assoc 1999; 282: 734.
26. Winkler C, Modi W, Smith MW et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279: 389-393.
27. Voevodin A, Samilchuk E, Dashti S. Frequencies of SDF-1 chemokine, CCR-5, and CCR-2 chemokine receptor gene alleles conferring resistance to human immunodeficiency virus type 1 and AIDS in Kuwaitis. J Med Virol 1999; 58: 54-58.
28. Kuipers H, Workman C, Dyer W, Geczy A, Sullivan J, Oelrichs R. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3′A allele. AIDS 1999; 13: 433-434.
29. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.
30. Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. Pharmacogenomics J 2002; 1: 243-253.